Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Céline David

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cell Communication and Signaling : CCS|October 5, 2023
The Golgi stacking protein GRASP55 is targeted by the natural compound prodigiosinLena Berning, Thomas Lenz, Ann Kathrin Bergmann, et al.
Cell Death & Disease|December 23, 2025
Small-molecule inhibitor of C‑terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cellsCéline David, Yadong Sun, Vitalij Woloschin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 18, 2021
Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factorsNicolas Meillan, Alexandre Orthuon, Paul Chauchat, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cell Communication and Signaling : CCS|October 5, 2023
The Golgi stacking protein GRASP55 is targeted by the natural compound prodigiosinLena Berning, Thomas Lenz, Ann Kathrin Bergmann, et al.
Cell Death & Disease|December 23, 2025
Small-molecule inhibitor of C‑terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cellsCéline David, Yadong Sun, Vitalij Woloschin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 18, 2021
Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factorsNicolas Meillan, Alexandre Orthuon, Paul Chauchat, et al.
Pageof 2